公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20170253591A1

公开(公告)日：2017-09-07

申请号：US15510225

申请日：2015-09-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoshi YAMAMOTO ,  Junya SHIRAI ,  Tsuneo ODA ,  Takashi IMADA ,  Mitsunori KONO ,  Ayumu SATO ,  Yoshihide TOMATA ,  Atsuko OCHIDA ,  Naoki ISHII ,  Yusuke SASAKI ,  Yoshiyuki FUKASE ,  Tomoya YUKAWA ,  Shoji FUKUMOTO

IPC: C07D471/04 ,  C07D413/12 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  C07D239/96 ,  C07D409/14 ,  C07D403/12 ,  C07D401/12 ,  C07D417/14 ,  C07D401/14 ,  C07D413/14

CPC classification number: C07D471/04 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  A61P1/00 ,  A61P11/00 ,  C07D239/96 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

公开(公告)号：US20160311811A1

公开(公告)日：2016-10-27

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato YOSHIDA ,  Kazuaki TAKAMI ,  Yusuke TOMINARI ,  Zenyu SHIOKAWA ,  Akito SHIBUYA ,  Yusuke SASAKI ,  Tony GIBSON ,  Terufumi TAKAGI

IPC: C07D413/14 ,  C07D401/14 ,  C07D403/14 ,  C07D403/04 ,  C07D495/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D409/14 ,  C07D471/10 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20240217957A1

公开(公告)日：2024-07-04

申请号：US18522917

申请日：2023-11-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Asato KINA ,  Zenichi IKEDA ,  Mitsunori KONO ,  Yuya OGURO ,  Osamu KUBO ,  Toru YAMASHITA ,  Kazuaki TAKAMI ,  Takafumi YUKAWA ,  Masaki SETO ,  Makoto KAMATA ,  Kenjiro SATO ,  Masataka MURAKAMI ,  Yusuke SASAKI ,  Matthew Thomas REYNOLDS ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Takuto KOJIMA ,  Keiko KAKEGAWA ,  Florian PÜNNER ,  Shinji NAKAMURA ,  Nao MORISHITA ,  Tadashi HIDAKA ,  Sachie TAKASHIMA ,  Takahiko TANIGUCHI

IPC: C07D413/04 ,  A61P25/00 ,  C07D413/14

CPC classification number: C07D413/04 ,  A61P25/00 ,  C07D413/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20190359587A1

公开(公告)日：2019-11-28

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu HIRAYAMA ,  Yasuhiro HIRATA ,  Yusuke TOMINARI ,  Naoki IWAMURA ,  Yusuke SASAKI ,  Moriteru ASANO ,  Terufumi TAKAGI ,  Masanori OKANIWA ,  Masato YOSHIDA ,  Shinichi IMAMURA

IPC: C07D401/04 ,  A61P35/00 ,  C07D409/14 ,  C07D401/14 ,  C07D417/14 ,  C07D407/14

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20190241566A1

公开(公告)日：2019-08-08

申请号：US16333296

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu HIRAYAMA ,  Yasuhiro HIRATA ,  Yusuke TOMINARI ,  Naoki IWAMURA ,  Yusuke SASAKI ,  Moriteru ASANO ,  Terufumi TAKAGI ,  Masanori OKANIWA ,  Masato YOSHIDA ,  Takashi ICHIKAWA ,  Shinichi IMAMURA

IPC: C07D473/28 ,  C07D473/40 ,  C07D519/00 ,  C07D471/04 ,  C07D417/14 ,  C07D413/14 ,  C07D401/14 ,  C07D409/14 ,  C07D405/14 ,  C07D401/04 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20150133451A1

公开(公告)日：2015-05-14

申请号：US14533326

申请日：2014-11-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki TAKAMI ,  Yusuke TOMINARI ,  Zenyu SHIOKAWA ,  Akito SHIBUYA ,  Yusuke SASAKI ,  Tony GIBSON ,  Terufumi TAKAGI

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。